The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules

被引：116

作者：

de la Torre, Beatriz G. ^{[1
]}

Albericio, Fernando ^{[2
,3
]}

机构：

[1] Univ KwaZulu Natal, Coll Hlth Sci, KRISP, ZA-4001 Durban, South Africa

[2] Univ KwaZulu Natal, Sch Chem & Phys, ZA-4001 Durban, South Africa

[3] Univ Barcelona, Networking Ctr Bioengn Biomat & Nanomed, Dept Organ Chem, CIBER BBN, E-08028 Barcelona, Spain

来源：

MOLECULES | 2020年 / 25卷 / 03期

基金：

新加坡国家研究基金会;

关键词：

antibodies; antibody drug conjugate; API; biologics; chemical entities; drug discovery; fluorine-based drugs; natural products; oligonucleotides; peptides; pyrazoles; TIDES; small molecules;

D O I：

10.3390/molecules25030745

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

During 2019, the US Food and Drug Administration (FDA) approved 48 new drugs (38 New Chemical Entities and 10 Biologics). Although this figure is slightly lower than that registered in 2018 (59 divided between 42 New Chemical Entities and 17 Biologics), a year that broke a record with respect to new drugs approved by this agency, it builds on the trend initiated in 2017, when 46 drugs were approved. Of note, three antibody drug conjugates, three peptides, and two oligonucleotides were approved in 2019. This report analyzes the 48 new drugs of the class of 2019 from a strictly chemical perspective. The classification, which was carried out on the basis of chemical structure, includes the following: Biologics (antibody drug conjugates, antibodies, and proteins); TIDES (peptide and oligonucleotides); drug combinations; natural products; and small molecules.

引用

页数：13

共 50 条

[1] The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules
de la Torre, Beatriz G.
Albericio, Fernando
[J]. MOLECULES, 2024, 29 (03):
[2] The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules
de la Torre, Beatriz G. G.
Albericio, Fernando
[J]. MOLECULES, 2023, 28 (03):
[3] The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules
de la Torre, Beatriz G.
Albericio, Fernando
[J]. MOLECULES, 2022, 27 (03):
[4] The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
de la Torre, Beatriz G.
Albericio, Fernando
[J]. MOLECULES, 2018, 23 (03):
[5] The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
de la Torre, Beatriz G.
Albericio, Fernando
[J]. MOLECULES, 2019, 24 (04):
[6] The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules
de la Torre, Beatriz G.
Albericio, Fernando
[J]. MOLECULES, 2021, 26 (03):
[7] The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type
de la Torre, Beatriz G.
Albericio, Fernando
[J]. MOLECULES, 2017, 22 (03)
[8] 2019 FDA drug approvals
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2020, 19 (2) : 79 - 84
[9] 2019 FDA drug approvals
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (02) : 79 - 84
[10] Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019
Bharate, Sonali S.
[J]. DRUG DISCOVERY TODAY, 2021, 26 (02) : 384 - 398

← 1 2 3 4 5 →